Three years after approval, court blocks US launch of Enbrel biosimilarSandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel Share XThree years after approval, court blocks US launch of Enbrel biosimilarhttps://pharmaphorum.com/news/three-years-after-approval-court-blocks-us-launch-of-enbrel-biosimilar/
Optimising market access for biosimilarsWe speak to Sandoz’s global head of biopharmaceuticals, Stefan Hendriks, about the remaining challenges in market access for Share XOptimising market access for biosimilarshttps://pharmaphorum.com/views-analysis-market-access/optimising-market-access-for-biosimilars/
Developing with start-up DNAAs head of digital at Sandoz, Andre Heeg is at the forefront of transformation both within his company Share XDeveloping with start-up DNAhttps://deep-dive.pharmaphorum.com/magazine/access-and-commercialisation/sandoz-andre-heeg-digital-startups/
Deep Dive: Access and CommercialisationIn this issue of Deep Dive we explore the ever present issues of market access and commercialisation, analysing Share XDeep Dive: Access and Commercialisationhttps://pharmaphorum.com/digital/pharma-access-commercialisation/
Sandoz strikes deal with EirGenix for Herceptin biosimilarSandoz has struck a deal with Taiwan-based EirGenix to market a late-stage biosimilar of Roche’s breast cancer blockbuster Share XSandoz strikes deal with EirGenix for Herceptin biosimilarhttps://pharmaphorum.com/news/sandoz-strikes-deal-with-eirgenix-for-herceptin-biosimilar/
Sandoz to commercialise opioid induced constipation tablet in EUAs it continues to look into drugs that can help opioid-dependant patients, Sandoz has signed an agreement with Shionogi Share XSandoz to commercialise opioid induced constipation tablet in EUhttps://pharmaphorum.com/news/sandoz-to-commercialise-opioid-induced-constipation-tablet-in-eu/
CEO of Novartis’ generics unit quits, sparking sale speculationRichard Francis is stepping down as CEO of Novartis’ generics and biosimilars division Sandoz at the end of Share XCEO of Novartis’ generics unit quits, sparking sale speculationhttps://pharmaphorum.com/news/ceo-of-sandoz-unit-quits-sparking-speculation-over-sale/
Sandoz announces results of digital innovation ‘HACk’A digital therapeutic for irritable bowel syndrome, a developing world disease diagnosis tool, and a mobile maternity clinic Share XSandoz announces results of digital innovation ‘HACk’https://pharmaphorum.com/news/sandoz-announces-results-of-digital-innovation-hack/
Sandoz selects finalists in digital tech healthcare access competitionSandoz has selected three finalists in a competition to use digital technology to increase access to medicines in Share XSandoz selects finalists in digital tech healthcare access competitionhttps://pharmaphorum.com/news/sandoz-selects-finalists-in-digital-tech-healthcare-access-competition/
